Sutro Biopharma, INC 10-Q quarterly reports

Sutro Biopharma's Q2 2026 filing reveals a substantial revenue decrease driven by the termination of the Ipsen collaboration, alongside continued net losses, though clinical development for STRO-004 shows early promise.

Sutro Biopharma reported a reduced net loss in Q3 2025, driven by strategic restructuring and a sharpened focus on its preclinical ADC pipeline, while addressing Nasdaq listing compliance.

Sutro Biopharma reported a reduced net loss and increased revenue driven by a strategic restructuring, deprioritizing STRO-002 and STRO-003 programs while focusing on preclinical assets STRO-004 and STRO-006, amidst a 50% workforce reduction and Nasdaq listing concerns.

Sutro Biopharma reports Q1 2025 results, details restructuring plan involving pipeline prioritization and workforce reduction.

Sutro Biopharma's Q3 2024 report reveals a net loss of $48.8 million, alongside updates on clinical trials and collaborations.

Sutro Biopharma's second quarter 2024 results show increased revenue driven by collaborations, alongside significant R&D spending and a net loss, while highlighting key clinical advancements.

Sutro Biopharma's first quarter 2024 results show increased revenue from collaborations, offset by higher R&D spending and a net loss, while also highlighting key clinical advancements and a new licensing agreement.